Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial
Background: Predictive biomarkers for immune checkpoint blockade in the second-line treatment of metastatic renal cell carcinoma (mRCC) are lacking. Materials and methods: Patients with histologically confirmed RCC who started nivolumab after at least 4 months of tyrosine kinase inhibitors (TKIs) we...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2024-06-01
|
| Seri Bilgileri: | Immuno-Oncology and Technology |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2590018824000091 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|